News
LivaNova Reports Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Almirall’s Full-Year 2022 Results
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
Financial highlights (€ rounded million)
Chemed Corporation Declares Quarterly Dividend of 38 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on March 17, 2023, to
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering
Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with
QIAGEN erhält CE-Kennzeichnung für Tuberkulose-Bluttest QuantiFERON-TB Gold Plus nach EU-Verordnung über In-vitro-Diagnostika (IVDR)
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Zertifizierung von QuantiFERON-TB Gold Plus (QFT-Plus) – dem weltweit führenden Tuberkulose-Bluttest – gemäß der EU-Verordnung
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the certification of QuantiFERON-TB Gold Plus (QFT-Plus) – the world’s leading tuberculosis (TB) blood test – under the
Premier’s PINC AI™ Receives 2023 Best in KLAS Award for Value-Based Care Consulting
PINC AI™, the technology and services platform of Premier Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been awarded the 2023 Best in KLAS designation for
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2022 results on Monday, February 27, 2023, after the close of the market. Acadia
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Chemed To Report Fourth-Quarter 2022 Earnings February 23, Related Conference Call To Be Held On February 24
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2022, on Thursday, February 23, 2023, following the close of trading
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22nd, before the market
Xencor to Present at the SVB Securities Global Biopharma Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
QIAGEN übertrifft Prognose für viertes Quartal und Gesamtjahr 2022 und steigert Umsatz mit Nicht-COVID-Produkten im Jahr 2022 um 14% (CER)
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ergebnisse für das vierte Quartal und das Gesamtjahr 2022 bekannt gegeben.
Der Konzernumsatz sank im vierten Quartal 2022 um
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2022.
Net sales for Q4 2022 declined 14% to $498 million from Q4 2021. Sales at CER